• Mashup Score: 3

    Acute myeloid leukemia (AML) treatment is challenging in older patients. There is a lack of evidence-based recommendations for older patients ≥70, a group largely underrepresented in clinical trials. With new treatment options being available in recent years, recommendations are needed for these patients. As such the International Society of Geriatric Oncology (SIOG) assembled a task force to review the evidence specific to treatment and outcomes in this population of patients ≥70 years. Six questions were selected by the expert panel in domains of (1) baseline assessment, (2) frontline therapy, (3) post-remission therapy, (4) treatment for relapse, (5) targeted therapies, and (6) patient reported outcome/function and enhancing treatment tolerance.

    Tweet Tweets with this article
    • Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG) https://t.co/4Olmhr6zZf @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Guidelines

  • Mashup Score: 0

    Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy is transforming the care of patients with relapsed/refractory multiple myeloma (MM). Unfortunately, despite being a disease of older adults these patients remain under-represented in most pivotal clinical trials. We performed a systematic review and proportion meta-analysis of prospective clinical trials and observational studies of anti-BCMA CAR-T therapy in patients with MM with the aim to determine the efficacy and safety of this therapy in older adults (≥65 years).

    Tweet Tweets with this article
    • Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis https://t.co/fO900h0XcF @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #CellularTherapy #CARTTherapy https://t.co/pineBpKNy2

  • Mashup Score: 0

    Age is a major risk factor for sporadic colon cancer (CC). In the general population, the side of the tumor (right versus left) shows a possible significant prognostic effect, with right tumors displaying the worst outcome due to biological differences. However, little is known about the role of sidedness in the older population. We conducted a pooled analysis of observational and prospective studies to confirm or reject the hypothesis that side is a prognostic variable, even in older patients with CC.

    Tweet Tweets with this article
    • Prognostic relevance of sidedness in older patients with colon cancer: A review and pooled analysis of 227,218 patients https://t.co/rpasJI4skQ @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Survival #MetaAnalysis https://t.co/Us3dN8IGPX